Suchergebnisse - "Fakih, Marwan G"

PubPharm (14)

1

Promoting antibody-dependent cellular phagocytosis for effective macrophage-based cancer immunotherapy

enthalten in: Science advances | 2022

von Cao, X. | Chen, J. | Li, B. | +9

2

Economic Analysis of Panitumumab Compared With Cetuximab in Patients With Wild-type KRAS Metastatic Colorectal Cancer That Progressed After Standard Chemotherapy

enthalten in: Clinical therapeutics | 2016

von Graham, C. | Maglinte, G. | Schwartzberg, L. | +6

3

Cost-minimization analysis of panitumumab compared with cetuximab for first-line treatment of patients with wild-type RAS metastatic colorectal cancer

enthalten in: Journal of medical economics | 2015

von Graham, C. | Hechmati, G. | Fakih, M. | +5

4

A phase II study of high-dose cetuximab plus irinotecan in colorectal cancer patients with KRAS wild-type tumors who progressed after standard dose of cetuximab plus irinotecan

enthalten in: Oncology | 2013

von Fora, A. | McMahon, J. | Wilding, G. | +4

5

Phase II study of irinotecan and cetuximab given every 2 weeks as second-line therapy for advanced colorectal cancer

enthalten in: Clinical colorectal cancer | 2012

von Carneiro, B. | Ramanathan, R. | Fakih, M. | +9

6

Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2010

von Reidy, D. | Vakiani, E. | Fakih, M. | +11

7

Stop and go FOLFOX plus bevacizumab chemotherapy in the first-line treatment of metastatic colorectal cancer

enthalten in: Oncology | 2010

von Vaidyanathan, G. | Groman, A. | Wilding, G. | +1

8

A phase II study of first-line biweekly capecitabine and bevacizumab in elderly patients with metastatic colorectal cancer

enthalten in: Critical reviews in oncology/hematology | 2009

von Puthillath, A. | Mashtare, T. | Wilding, G. | +6

9

Neoadjuvant chemoradiation for rectal cancer : is more better?

enthalten in: Oncology (Williston Park, N.Y.) | 2008

von Patel, A. | Puthillath, A. | Yang, G. | +1

10

Reversible grade 4 hyperbilirubinemia in a patient with UGT1A1 7/7 genotype treated with irinotecan and cetuximab

enthalten in: Clinical colorectal cancer | 2007

von Gupta, B. | LeVea, C. | Litwin, A. | +1